- My News
- All News
- Most Popular
CHICAGO & SAN ANTONIO--(BUSINESS WIRE)-- SimBioSys®, the technology company that predicts tumor responses to therapy, presented new research on the accuracy and specificity of their simulation software, TumorScope®, for breast cancer treatment planning during the 2021 San Antonio Breast Cancer Symposium (SABCS). The studies covering eight separate posters at SABCS are based on data from both internal and external validation studies of SimBioSys' proprietary platform. The results include biophysical simulations of neoadjuvant therapy (a preliminary step to begin shrinking a tumor); biological drivers for different racial groups including African Americans vs Caucasians; prognostic responses to identify the patients who will, or will not, benefit from various chemotherapies; and characterization of the tumor's microenvironment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005234/en/
TumorScope is a first-of-its-kind platform combining artificial intelligence with biophysical simulations to model the impact of phenomena such as drug delivery, metabolism, and spatial heterogeneity in a comprehensive model using standard-of-care data alone. The results are generated within minutes, enabling physicians to make a well-informed decision while improving patient experience and shared decision-making. In addition, the technology can support the drug development process across pre-clinical and clinical trial settings.
"Breast cancer continues to be at the forefront of the precision medicine movement, and yet clinicians have been unable to individualize care for patients. Beyond our clinical utility in treatment selection, we are excited to expand TumorScope for use in biopharma for clinical trial optimization and biomarker identification," said John Cole, Ph.D., Chief Scientific Officer at SimBioSys. "Having eight posters accepted at the SABCS speaks to the breadth of our platform. We are proud of the work and the results that our multidisciplinary R&D team has accomplished in breast cancer."
Key SimBioSys studies from the symposium include:
SimBioSys is a technology company that combines artificial intelligence and biophysical simulations to advance precision medicine in cancer care. The company's technology virtualizes individual tumors and through biophysical simulations delivers insights on specific traits, such as tumor morphology and vascularization, while simultaneously predicting response to therapy. SimBioSys' goal is to transform decision-making in cancer care by empowering physicians with a better understanding of each patient's disease. By virtually assessing each patient's response to treatment physicians can truly personalize therapy. For more information, visit https://www.simbiosys.com/.
Did you like this article?